Skip to main content
. 2015 Nov 18;29(18):2447–2457. doi: 10.1097/QAD.0000000000000862

Fig. 1.

Trial profile.

Fig. 1

LPV, lopinavir; NRTI, nucleoside reverse-transcriptase inhibitor.